Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 145 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperparathyroidism Clear all
Completed Phase 1Phase 2 Interventional

The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients

NCT00508885
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Niacinamide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2007 · Synced Jul 21, 2026, 6:55 PM EDT
Recruiting Phase 4 Interventional

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

NCT03935984
View directory record Official record
Conditions
Primary Hyperparathyroidism, Hypercalcemia
Interventions
Calcitonin
Drug
Lead sponsor
Joseph Sferra
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 21, 2026, 6:55 PM EDT
Active, not recruiting Not applicable Interventional

Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis

NCT00169806
View directory record Official record
Conditions
Nephrocalcinosis, Renal Calculi, Hypercalciuria, Hyperparathyroidism, Cystinuria
Interventions
videotape for mapping of renal anatomy and papillary biopsy
Other
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 21, 2026, 6:55 PM EDT
Completed No phase listed Observational

Renal Osteodystrophy: A Fresh Approach

NCT00859612
View directory record Official record
Conditions
Renal Osteodystrophy
Interventions
Not listed
Lead sponsor
Hartmut Malluche, MD
Other
Eligibility
18 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)

NCT00792857
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTAP201 Injection, Doxercalciferol
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Jul 21, 2026, 6:55 PM EDT
Terminated No phase listed Observational

F-18 PSMA for Localization of Parathyroid Adenoma

NCT05299632
View directory record Official record
Conditions
Hyperparathyroidism
Interventions
99mTc-MIBI planar imaging and SPECT/CT., F- 18PSMA PET/CT imaging study
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Results available

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

NCT02833857
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Louisville, Kentucky • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Jul 21, 2026, 6:55 PM EDT
Terminated Phase 4 Interventional Results available

Denosumab in Primary Hyperparathyroidism

NCT01558115
View directory record Official record
Conditions
Primary Hyperparathyroidism
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

Cinacalcet to Treat Familial Primary Hyperparathyroidism

NCT00325104
View directory record Official record
Conditions
Hypercalcemia, Familial Primary Hyperparathyroidism
Interventions
Parathyroid hormone testing, Serum calcium testing
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

NCT01704079
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions
CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
Drug · Other
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy

NCT02205801
View directory record Official record
Conditions
Thyroid Neoplasms, Goiter, Nodular, Thyroid Nodule, Graves' Disease, Hyperparathyroidism
Interventions
Superficial Cervical Plexus Block, Local Wound Infiltration, 0.9% saline, Marcaine
Procedure · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Jul 21, 2026, 6:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vitamin D Deficiency in Elderly African American Women in Central Texas

NCT01971411
View directory record Official record
Conditions
Vitamin D Deficiency, Osteoporosis, Osteopenia
Interventions
Calcium 500mg with 200 IU Vitamin D - 2 tablets daily, Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH, Usual sun exposure documentation, Dietary intake of calcium, vitamin D, magnesium
Drug · Procedure · Behavioral
Lead sponsor
McLennan County Medical Education and Research Foundation
Other
Eligibility
70 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas

NCT04895631
View directory record Official record
Conditions
Hyperparathyroidism, Primary
Interventions
18F-Fluorocholine, Positron emission tomography (PET)
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
13 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 21, 2026, 6:55 PM EDT
Not yet recruiting Phase 2 Interventional

Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD

NCT07654231
View directory record Official record
Conditions
Chronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, Dyslipidemia, Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (Stage 3)
Interventions
Low-dose Colchicine at 0.5mg daily, Usual Care
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

NCT01785849
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

NCT01896232
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Etelcalcetide, Cinacalcet, Oral Placebo, Intravenous Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
41
States / cities
Azusa, California • Bakersfield, California • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

NCT00463021
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
8
States / cities
Downey, California • Paramount, California • Hudson, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

NCT00053547
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End Stage Renal Disease
Interventions
paricalcitol injection
Drug
Lead sponsor
Abbott
Industry
Eligibility
2 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Stanford, California • Miami, Florida • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced Jul 21, 2026, 6:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

NCT07083557
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions
Endothelial cell collection
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Results available

How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis

NCT00528788
View directory record Official record
Conditions
Hyperparathyroidism, Secondary, Kidney Failure, Chronic
Interventions
doxercalciferol
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

NCT02525796
View directory record Official record
Conditions
Primary Hyperparathyroidism
Interventions
eplerenone, amiloride, Placebo, Cinacalcet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jul 21, 2026, 6:55 PM EDT
Completed Not applicable Interventional

Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease

NCT00781417
View directory record Official record
Conditions
Kidney Disease
Interventions
Vitamin D, Placebo
Dietary Supplement · Other
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Jul 21, 2026, 6:55 PM EDT
Terminated No phase listed Observational

Gene Expression in Hyperparathyroidism

NCT03044600
View directory record Official record
Conditions
Parathyroid Disease, Hyperparathyroidism
Interventions
Chart Review, HRPT2 Mutation Evaluation
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Jul 21, 2026, 6:55 PM EDT
Terminated Not applicable Interventional

Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant

NCT01011114
View directory record Official record
Conditions
Hypophosphatemia, Renal Transplant
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Jul 21, 2026, 6:55 PM EDT